Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 9/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631353 | 0.86 | GPR119 (0.54) | RBP4LMNAGPR119MAPT | |
| SCHEMBL532719 | 0.82 | HTT (0.49) | SLC6A9SLC6A5LMNAMAPTMAPK1 | |
| SCHEMBL18240930 | 0.82 | CHRM4 (0.42) | RBP4SMN1; SMN2 | |
| SCHEMBL709690 | 0.81 | MAPT (0.49) | SLC6A9SLC6A5LMNAMAPTMAPK1 | |
| SCHEMBL766289 | 0.80 | RBP4 (0.74) | RBP4LMNAMAPTMAPK1HTT | |
| SCHEMBL20524591 | 0.80 | KDM4E (0.44) | SLC6A9SLC6A5LMNAMAPTMAPK1 | |
| SCHEMBL4147771 | 0.80 | SLC6A9 (0.56) | SLC6A9SLC6A5LMNAMAPTMAPK1 | |
| SCHEMBL631019 | 0.78 | RBP4 (0.52) | RBP4LMNAMAPK1HTTKMT2A | |
| SCHEMBL248276 | 0.78 | LMNA (0.52) | SLC6A9SLC6A5LMNAKCNH2 | |
| SCHEMBL25369348 | 0.77 | GPR119 (0.55) | SLC6A9LMNAGPR119MAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2419413-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | RBP4 1/4885SLC6A9 4689/4885SLC6A5 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.